Health authorities in the Democratic Republic of the Congo began administering the Ervebo vaccine to frontline staff in Bunia on September 19, 2026, as the country’s largest-ever Ebola outbreak crossed 7,541 confirmed cases and 3,639 deaths, driven by the Bundibugyo virus strain.
The current health crisis, officially declared on May 15, has surpassed all previous epidemic totals recorded in the country.
Ervebo Vaccine Rollout Targets Frontline Workers in Ituri Province
Vaccination efforts expanded sharply on September 19, 2026, reaching Bunia, the capital of Ituri Province, which serves as the epicenter of the transmission wave. Gaby Kasongo Mulumba, governor of Ituri Province, received an initial dose alongside local medical personnel. Authorities are prioritizing doctors, nurses, and support staff due to their heightened exposure.
The rollout is backed by the World Health Organization and Doctors Without Borders, known by its French initials MSF according to regional coverage. The International Coordinating Group on Vaccine Provision approved an initial allocation of 70,000 doses of the Ervebo vaccine in August as announced by UN health officials. Of that total, 50,000 doses are designated for compassionate use among healthcare and frontline personnel, while 20,000 doses are reserved for a Phase 3 clinical trial managed through scientific partners.
Medical workers face difficult choices on the ground. Dr. Jeannot Elua described the mandatory nature of the immunization protocols at a local health facility in Bunia in statements given to wire reporters.
Uncertain Cross-Protection Against the Bundibugyo Strain
A core scientific challenge defines the vaccination campaign: Ervebo was manufactured and licensed to combat the Zaire ebolavirus strain, whereas the current epidemic is driven by the Bundibugyo virus according to the Africa Centers for Disease Control and Prevention. No licensed vaccines or specific antiviral treatments currently exist for the Bundibugyo strain as noted by international health agencies.
While early laboratory and animal testing indicate that Ervebo may offer partial cross-protection, its actual efficacy in humans exposed to the Bundibugyo virus remains unverified per assessments released by the World Health Organization. Placide Mbala-Kingebeni of the Congolese National Institute of Biomedical Research noted that anecdotal observations from previous outbreaks showed health workers who previously received Ervebo suffered less severe illness when infected subsequently at an Africa CDC press briefing.
Prof. Steve Ahuka, a senior official within the Congolese health task force, emphasized the existing knowledge gap during official updates.
“We don’t know to what degree it might be effective against the Bundibugyo strain.”
Clinical Trials and Exponential Spread Across Eastern Provinces
To rigorously evaluate the vaccine, health agencies launched the BRAVO study in Bunia as detailed in scientific briefings. The protocol is designed to monitor approximately 20,000 frontline workers across Ituri and North Kivu provinces over a nine-to-twelve-month period. Parallel safety trials for newer experimental vaccines developed by Oxford University and Moderna are underway in the United Kingdom and Canada as reported by UN Director-General Tedros Adhanom Ghebreyesus, with efficacy trials in the DRC anticipated around October or November.
Containment efforts face compounding obstacles. Julien Harneis, the UN’s Ebola coordinator, told reporters from Bunia that the geographic spread of the virus covers an area larger than France in updates on operational conditions. Harneis characterized the response environment as brutal, citing armed groups, fractured local infrastructure, and repeated security restrictions that have hindered contact tracing and safe burials.
Nearly 160 healthcare workers have contracted the virus during the current wave, resulting in over 40 deaths among medical staff according to UN figures. With weekly fatalities reaching new highs and transmission outpacing response capacity, the International Health Regulations Emergency Committee has called for immediate, coordinated scale-ups in isolation centers and community engagement to prevent broader regional transmission into neighboring states.
Продолжение темы
